Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Endocrinology | Dermatology/Plastic Surgery
Disease Category: Diabetic Foot Ulcers
Trial Information
A Multicenter, Randomized, Double-Blind, Comparison Study Of The Safety And Efficacy Of A Once-Daily Dose Of Tigecycline Versus Ertapenem For The Treatment Of Foot Infections In Subjects With Diabetes
Diagnosis:
Men and women aged 18 or older with diabetes and a qualifying foot
infection
Qualifying subjects will be randomly assigned (in a 1:1 ratio)
to receive either tigecycline or ertapenem via intravenous (IV)
administration for up to 28 consecutive days. Subjects receiving
ertapenem may also receive vancomycin for MRSA, coagulase-negative
staphylococci (CNS), or enterococci coverage at the investigator’s
discretion.
Goal:
This is a comparison study of the safety and efficacy of a
once-daily dose of Tigecycline versus Ertapenem for the Treatment
of Foot Infections in Subjects with Diabetes
Investigators:
- Lance R. Peterson, MD (Principal Investigator)
- Michael Howard, MD (Co-Investigator)
Sponsors:
Lance R. Peterson
Evanston Northwestern Healthcare
2650 Ridge Ave
Evanston, IL 60201
Phone: 847-570-1637
View Google Map
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.